Hoth Therapeutics Completes $3M Series A Financing

Hoth Therapeutics Inc., a Nevada based development stage biopharmaceutical company, also known as eczema, completed a $3m Series A financing.

The backers remained undisclosed.

The company intends to use the funds to advance its BioLexa Platform.

Led by Robb Knie, CEO, Hoth is a development stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema.



Join the discussion